Enlivex Ltd. is facing a significant challenge as it received a delisting notification from Nasdaq due to its ordinary shares not meeting the minimum bid price requirement. The company plans to appeal this decision, which could impact its trading status on the Nasdaq Capital Market.
On October 26, 2026, Enlivex received the Delisting Notice from Nasdaq's Listing Qualifications Department. The notice stated that the company's ordinary shares had not maintained a closing bid price of at least $1.00 for 30 consecutive business days prior to October 22, 2026. Due to a reverse stock split within the last 12 months, Enlivex is not eligible for the usual 180-day grace period to regain compliance with this requirement.
Enlivex, which operates under the ticker ENLV on Nasdaq, is a company based in Tel Aviv, Israel, specializing in finance services. The company is known for its dual strategy that combines the development of longevity therapeutics with a prediction markets treasury strategy. Its primary clinical focus is on Allocetra™, an immunotherapy targeting age-related inflammatory conditions.
According to the filing, Enlivex intends to appeal the delisting determination by submitting a request for an oral hearing before the Nasdaq Hearings Panel. This appeal will temporarily halt any suspension or delisting actions while the hearing is pending, allowing the company’s ordinary shares to continue trading on the Nasdaq Capital Market.
In an effort to regain compliance with Nasdaq's listing rules, Enlivex has undertaken a 1-for-16 reverse stock split, which became effective on the same day as the delisting notification. However, the company has acknowledged that it cannot guarantee the success of its appeal or that its shares will continue to trade on Nasdaq after the hearing.
This situation is particularly significant for Enlivex as it highlights the challenges faced by companies in the finance services sector, especially those struggling to meet regulatory compliance. The outcome of the appeal could set a precedent for other companies in similar situations.
As of the filing date, Enlivex has not disclosed any further actions or upcoming filings related to this matter. The company continues to navigate this critical juncture in its operations and market presence.